The Impact of Erythropoietin on Short and Long-term Kidney-Related Outcomes in Extremely Low Gestational Age Neonates. Results of a Multi-center Double-Blind Placebo-Controlled Randomized Clinical Trial
To evaluate whether extremely low gestational age neonates (ELGANs) randomized to erythropoietin have better or worse kidney-related outcomes during hospitalization and at 22-26 months corrected gestational age (cGA) compared with those randomized to placebo.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: David J. Askenazi, Patrick J. Heagerty, Robert H. Schmicker, Patrick Brophy, Sandra E. Juul, Stuart L. Goldstein, Sangeeta Hingorani, PENUT Trial Consortium Tags: Original Articles Source Type: research